Anticoagulation in cirrhosis: Ready ... set ... wait!

Hepatology

Volumn 58, Issue 3, 2013, Pages 1175-1176

  Seijo, Susana ^a   Garcia Pagan, Juan Carlos ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FOLLOW UP; HEPATOLOGIST; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; OUTPATIENT; PORTAL VEIN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROBABILITY; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR PATENCY;

ANTICOAGULANTS; DNA, BACTERIAL; ENOXAPARIN; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE; MALE; RENAL VEINS; THROMBOSIS;

EID: 84883222893     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26503     Document Type: Article

References (17)

1. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000;31:345-348.
2. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.
3. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736-741.
4. Zocco MA, Di SE, De CR, Novi M, Ainora ME, Ponziani F, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009;51:682-689.
5. Keiding S, Solvig J, Gronbaek H, Vilstrup H. Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis. Scand J Gastroenterol 2004;39:594-599.
6. Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009;51:632-634.
7. Anstee QM. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008;6:1336-1343.
8. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008;6:2-9.
9. Duplantier JG. A role for thrombin in liver fibrosis. Gut 2004;53:1682-1687.
10. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010;44:448-451.
11. Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-783.
12. Senzolo M, Sartori M, Rossetto V, Burra P, Cillo U, Boccagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919-927.
13. Abe W. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol 2007;46:286-294.
14. Abdel-Salam OM. A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharm Res 2005;51:59-67.
15. Assy N. The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. Dig Dis Sci 2007;52:1187-1193.
16. Lee J H. The use of low molecular weight heparin-pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway. Biomaterials 2011;32:1438-1445.
17. Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012;143:1253-1260.